Table 1. Patient characteristics . .... | American Society of Hematology

Table 1.

Patient characteristics

		Patients with MRD follow-up
Variable	Patients	MRD positive	MRD negative
*No.*	29*	13	14
Age, y (range)	56 (38-68)	56 (41-61)	56 (38-68)
*Men/women, no.*	*24/5*	*13/0*	*10/4*
Disease stage, no.
II	1	0	1
III	3	2	1
IV	25	11	12
Induction treatment, no.
*COP*	2	1	1
CHOP	26	12	12
*PmM*	1	0	1
Disease status before ASCT, no.
CR	7	1	6
PR	17	10	6
*Second PR*	4	2	1
MR	1	0	1
Disease status after ASCT, no.
CR	22	6	14
PR	7	7	0
*Rituximab exposure, no.*	12	3	9
LDH abnormal, no.	4†	0†	4
*Extranodal site, no.*	*15‡*	8†	6†
BM involvement, no.	19	10	7
*Bulky disease, no.*	*12†*	7	5†
Spleen enlargement, no.	12†	6	5†

		Patients with MRD follow-up
Variable	Patients	MRD positive	MRD negative
*No.*	29*	13	14
Age, y (range)	56 (38-68)	56 (41-61)	56 (38-68)
*Men/women, no.*	*24/5*	*13/0*	*10/4*
Disease stage, no.
II	1	0	1
III	3	2	1
IV	25	11	12
Induction treatment, no.
*COP*	2	1	1
CHOP	26	12	12
*PmM*	1	0	1
Disease status before ASCT, no.
CR	7	1	6
PR	17	10	6
*Second PR*	4	2	1
MR	1	0	1
Disease status after ASCT, no.
CR	22	6	14
PR	7	7	0
*Rituximab exposure, no.*	12	3	9
LDH abnormal, no.	4†	0†	4
*Extranodal site, no.*	*15‡*	8†	6†
BM involvement, no.	19	10	7
*Bulky disease, no.*	*12†*	7	5†
Spleen enlargement, no.	12†	6	5†

Two of 29 patients had insufficient DNA samples for MRD analysis within the first year after ASCT.

Status was not documented in 1 patient.

Status was not documented in 2 patients.